JONTISAVE

(Zoledronic Acid Monohydrate) B.P

R

Paget’s disease of bone

Bone metastases (breast, prostate, multiple myeloma).

R

Hypercalcemia of malignancy

Prevention of skeletal-related events in cancer patients.

Mechanism of Action

$

Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking the mevalonate pathway → increases bone density and reduces fracture risk.

Administration

$

Given as slow IV infusion (usually ≥15 minutes)

$

Ensure adequate hydration

$

Supplement with calcium + vitamin D

Dosage (Common)

$

Osteoporosis: 5 mg IV once yearly

$

Cancer-related bone disease: 4 mg IV every 3–4 weeks

Side Effects

$

Flu-like symptoms (fever, myalgia)

$

Bone, joint, or muscle pain

$

Hypocalcemia

$

Renal toxicity (if infused rapidly or in renal disease)

$

Rare: Osteonecrosis of the jaw (ONJ), atypical femur fractures

$

Contraindications / Precautions

$

Severe renal impairment

$

Hypocalcemia (must be corrected before use)

$

JONTISAVE

(Zoledronic Acid Monohydrate) B.P

Paget’s disease of bone

Hypercalcemia of malignancy

Mechanism of Action

Zoledronic acid inhibits osteoclast-mediated bone resorption by blocking the mevalonate pathway → increases bone density and reduces fracture risk.

Administration

Given as slow IV infusion (usually ≥15 minutes)

Ensure adequate hydration

Supplement with calcium + vitamin D

Dosage (Common)

Osteoporosis: 5 mg IV once yearly

Cancer-related bone disease: 4 mg IV every 3–4 weeks

Side Effects

Flu-like symptoms (fever, myalgia)

Bone, joint, or muscle pain

Hypocalcemia

Renal toxicity (if infused rapidly or in renal disease)

Rare: Osteonecrosis of the jaw (ONJ), atypical femur fractures

Contraindications / Precautions

Severe renal impairment

Hypocalcemia (must be corrected before use)

Dental examination recommended before long-term therapy